05/12/2017 07:02:27

Update on NeuroSearch’s business status and future

Related content
17 Nov - 
NeuroSearch upgrades its guidance for 2017
31 Aug - 
NeuroSearch A/S – H1 report 2017
04 Jul - 
NeuroSearch and Saniona enter into agreement on transfe..
Related debate
19 Dec - 
Lige nu er muligheden i Neurosearch at købe billigt og ..
14 Dec - 
14 Dec - 
Jeg opfatter nu ikke nohopes indlæg som specielt rettet..

Company announcement

5 December 2017

In the annual report for 2016, the Board of Directors informed that the Company would continue the work to dispose its remaining assets and liabilities, and that a sale of the Company, including the tax loss, would remain an option. The Board of Directors also stated that it would endeavour to have a final clarification of the Company’s future by the end of 2017.

The Company has met most of the objectives of its action plan, which therefore now enters the final phase, during which the Company will either be divested or liquidated.

All significant outstanding obligations have been, or are currently being settled. On 4 July 2017, the Company announced that the remaining rights in the preclinical and clinical assets which NeuroSearch divested to Saniona during the period 2012-2016 had been sold to Saniona A/S for a one-time payment of DKK 5.5 million. Further, Saniona assumed NeuroSearch’s royalty obligations to third parties regarding potential future net sales of products from the projects in question, including NeuroSearch’s royalty payment obligations to Boehringer Ingelheim on tesofensine and to GlaxoSmithKline on NS2359. The liquidation of NsGene has also been completed.

Hereafter, the remaining assets consist of:


  • Cash and cash equivalents of approximately DKK 75 million

  • A small illiquid shareholding in Atonomics A/S

  • Potential milestone payments from Teva Pharmaceuticals totalling DKK 55 million, which will become payable if the drug candidate Huntexil® is granted market approval. The Company has no insight into Teva Pharmaceuticals further plans for development of Huntexil®

  • A tax loss of about DKK 1.6 billion, which may be carried forward indefinitely

In light of the above, the Company is now at a stage of its resolution plan at which it intends to explore the possibility of divesting the Company during the coming months. If the Company does not receive a satisfactory bid, the Board of Directors expects to propose to the shareholders at the annual general meeting to be held in spring 2018 that the Company enter into voluntary liquidation in order to distribute the net proceeds to the shareholders.

Financial outlook for 2017

In 2017, NeuroSearch expects an operating loss of approximately DKK 1 million. The outlook does not include any income from the possible divestment of additional Company assets or potential income from the Company’s agreement with Teva Pharmaceuticals.


Allan Andersen, CEO, telephone: +45 4016 3864

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on NASDAQ Copenhagen A/S.


Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Alliance Trust PLC : Net Asset Value(s)

23/01/2018 13:47:03
ALLIANCE TRUST PLC                                    At the close of business on Monday 22 January 2018: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 814.7p -       including income, 818.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Investec Bank plc : Form 8.5 (EPT/RI) - Melrose Industries plc

23/01/2018 10:51:00
 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Man Group PLC : Form 8.3 - [UBM plc] - Amendment

22/01/2018 14:52:32
Amendment to cash-settled derivatives positions and transactions, sections 2(a) and 3(b). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Post-stabilisation Pbb € 500mn senior 2022
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
Southern Missouri Bancorp Reports Preliminary Results for Second Quarter of Fiscal 2018; Dividend of $0.11 Per Common Share Declared; Conference Call to Discuss Results Scheduled for Tuesday, January 23 at 3:30 P.m. Central Time
Simmons Reports Fourth Quarter 2017 Earnings
Microdrones and ASPRS to host Workshop Day, February 8th, in conjunction with the ILMF and ASPRS Conference in Denver, Colorado

Related stock quotes

NeuroSearch A/S 4.40 0.2% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
23 January 2018 15:32:17
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180122.2 - EUROWEB3 - 2018-01-23 16:32:17 - 2018-01-23 15:32:17 - 1000 - Website: OKAY